# Chimerix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chimerix

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.chimerix.com
- Total disclosed funding: $102M
- Latest round: Series F (Feb 14, 2011)
- Investors on record: 8

## About

Chimerix, Inc. is a biopharmaceutical company focused on developing innovative medicines to treat cancer and other serious diseases, specializing in unique compounds known as imipridones.Founded in 2002 and headquartered in Durham, US, Chimerix, Inc. specializes in the development of pharmaceuticals aimed at oncology. The company has undergone significant funding events, notably raising USD 102.48 million in an IPO in April 2013, and USD 40.87 million in a public offering in October 2013. Its total amount raised is USD 37.38 mn. The firm’s founder and CEO information is not disclosed.Chimerix specializes in developing innovative medicines targeting cancer and other serious diseases, positioned under the oncology sector. The company's core product offerings primarily include imipridones, with notable compounds such as ONC201, ONC206, and ONC212, designed to address various types of tumors, including gliomas and central nervous system tumors. These imipridones function by leveraging unique mechanisms to inhibit tumor growth and promote cancer cell death, thereby providing potential therapeutic solutions for patients. Chimerix's products are targeted at healthcare professionals and institutions involved in oncology, with a focus on markets in the United States and select regions in Europe, catering to hospitals, cancer treatment centers, and research institutions.Chimerix generated USD 212,000 in revenue for the most recent fiscal year 2024, with an EBITDA of USD -93,001,000. Its revenue model primarily involves partnerships with healthcare providers and research organizations, facilitating access to its pharmaceutical offerings through direct B2B agreements for clinical use and expanded access programs. The flagship products, especially the imipridones, form the cornerstone of its revenue strategy.Chimerix plans to further develop its imipridone compounds and is exploring new therapeutic areas within oncology. The company is targeting expanded market presence in specific regions of Europe by 2025. Recent funding will be allocated to R&D and market expansion initiatives, enhancing its product pipeline and broadening its reach in the oncology sector.

## Funding rounds

- Series F, Feb 14, 2011, $45M — Alta Partners, Frazier Healthcare Partners, Sanderling Ventures, Canaan Partners, Pappas Capital, New Leaf Venture Partners, 5Y Capital, Asset Management Ventures
- Series E, Jul 24, 2009, $16M — Alta Partners, Sanderling Ventures, Canaan Partners, Asset Management Ventures
- Series D, Feb 23, 2007, $23M — Alta Partners, Frazier Healthcare Partners, Sanderling Ventures, Canaan Partners, Asset Management Ventures
- Series C, Jul 7, 2006, $1.5M — Asset Management Ventures
- Series C, Nov 4, 2004, $11M — Frazier Healthcare Partners, Sanderling Ventures, Asset Management Ventures
- Series B, Sep 8, 2003, $3.1M — Sanderling Ventures, Asset Management Ventures
- Series A, Jul 1, 2002, $2.2M — Sanderling Ventures, Asset Management Ventures

## Investors

- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series A, Series B, Series C, Series D, Series E, Series F
- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series A, Series B, Series C, Series D, Series E, Series F
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series C, Series D, Series F
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series D, Series E, Series F
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series D, Series E, Series F
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series F
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series F
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series F